American pharmaceutical giant Pfizer has submitted an application to European regulators to approve the use of Axitinib, which is a drug for treating kidney cancer patients.
Axitinib is consumed orally and has been developed to block receptors that influence tumor growth, blood vessel growth, and spread of cancers.
AdvertisementPfizer revealed that its application has been accepted by the European Medicines Agency and added that it will be providing more data from the late-stage trial of the drug later this week at the American Society of Clinical Oncology meet.
P FDA Says No Link Between Popular Antihypertensive Drugs and Cancer Honeysuckle Extract is a Natural UV Protecting Agent M
You May Also Like